Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor–Resistant Disease
نویسندگان
چکیده
منابع مشابه
Epidermal growth factor receptor tyrosine kinase inhibitor-resistant disease.
PURPOSE EGFR-mutant lung cancer was first described as a new clinical entity in 2004. Here, we present an update on new controversies and conclusions regarding the disease. METHODS This article reviews the clinical implications of EGFR mutations in lung cancer with a focus on epidermal growth factor receptor tyrosine kinase inhibitor resistance. RESULTS The discovery of EGFR mutations has a...
متن کامل2D-QSAR and docking studies of 4-anilinoquinazoline derivatives as epidermal growth factor receptor tyrosine kinase inhibitors
Introduction: Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor derivatives play an important role in the treatment of cancer. We aim to construct 2D-QSAR models using various chemometrics using 4-anilinoquinazoline-containing EGFR TKIs. In addition, the binding profile of these compounds was evaluated using a docking study. Materials and Methods: In this study, 122 compounds of...
متن کاملRegulatory control of the epidermal growth factor receptor tyrosine kinase.
The epidermal growth factor (EGF) receptor has been shown to posses an intrinsic tyrosine protein kinase activity that is stimulated by the binding ofEGF [1]. In addition, two other ligands for the EGF receptor can stimulate the tyrosine protein kinase activity in intact cells: TGF-(X (transforming growth factor (X) and a soluble biosynthetic precursor of TGF-(X [2, 3]. Analysis of the kinetics...
متن کاملCalmodulin inhibits the epidermal growth factor receptor tyrosine kinase.
We demonstrate in this report that the epidermal growth factor (EGF) receptor from rat liver can be isolated by calmodulin affinity chromatography by binding in the presence of Ca2+ and elution with a Ca(2+)-chelating agent. The bulk of the EGF receptor is not eluted by a NaCl gradient in the presence of Ca2+. We ascertained the identity of the isolated receptor by immunoblot and immunoprecipit...
متن کاملShould Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor Be Continued beyond Progressive Disease?
Epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) is almost exclusively effective in patients with activating EGFR mutations, and median time to progression in such patients is generally up to 12 months. Usually, treatment with EGFR-TKI is terminated when disease progression is confirmed; however, acute exacerbation after the withdrawal of EGFR-TKI has been reported. In this...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Journal of Clinical Oncology
سال: 2013
ISSN: 0732-183X,1527-7755
DOI: 10.1200/jco.2012.43.3912